| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | uPA |
| Uniprot No | P00749 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-431aa |
| 氨基酸序列 | SNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTC YEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN YCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQ KTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVI SATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTL AHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGK ENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTD SCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR SHTKEENGLAL |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于uPA(尿激酶型纤溶酶原激活剂)重组蛋白的模拟参考文献示例(内容为虚构，供参考)：
---
1. **文献名称**: "Recombinant uPA: Structural Characterization and Functional Analysis in Fibrinolysis"
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌表达系统成功制备重组uPA蛋白，解析其三维结构，并验证其通过激活纤溶酶原促进纤维蛋白溶解的功能，为溶栓治疗提供新策略。
2. **文献名称**: "Role of uPA in Tumor Metastasis: Insights from Recombinant Protein-Based Models"
**作者**: Johnson R, et al.
**摘要**: 利用重组uPA蛋白研究其在癌细胞侵袭中的作用，发现uPA通过激活纤溶酶原降解细胞外基质，促进肿瘤转移，提示其作为癌症治疗靶点的潜力。
3. **文献名称**: "Development of a Novel Recombinant uPA Variant with Enhanced Stability for Therapeutic Use"
**作者**: Lee H, et al.
**摘要**: 通过基因工程技术改造uPA蛋白，设计出半衰期延长且抗凝血活性增强的重组突变体，动物实验显示其溶栓效果优于天然uPA，安全性良好。
4. **文献名称**: "Expression and Purification of Functional uPA in Mammalian Cell Systems"
**作者**: Garcia M, et al.
**摘要**: 比较哺乳动物细胞(CHO)和原核系统表达重组uPA的差异，发现CHO细胞表达的uPA糖基化更完整，体外活性显著提高，适用于大规模生产。
---
**说明**：以上文献为模拟示例，真实文献需通过PubMed、Web of Science等学术平台检索关键词(如 "recombinant uPA"、"urokinase plasminogen activator")。
Urokinase-type plasminogen activator (uPA) is a serine protease that plays a critical role in fibrinolysis, tissue remodeling, and cell migration. Initially identified in urine, uPA is synthesized as a single-chain pro-enzyme (pro-uPA) and activated by proteolytic cleavage into a two-chain active form. Structurally, it consists of three domains: a growth factor-like domain mediating receptor binding, a kringle domain involved in protein interactions, and a catalytic domain responsible for enzymatic activity. uPA binds to its specific cell-surface receptor (uPAR), forming a complex that localizes plasminogen activation to cell surfaces, enhancing extracellular matrix degradation and facilitating cellular invasion.
Recombinant uPA is produced using genetic engineering techniques, often in mammalian expression systems to ensure proper post-translational modifications. Its therapeutic potential stems from its ability to convert plasminogen into plasmin, a broad-spectrum protease that dissolves blood clots. Clinically, recombinant uPA derivatives like alteplase are used as thrombolytic agents for acute myocardial infarction and stroke. Beyond fibrinolysis, uPA is implicated in cancer progression, as tumor cells exploit its proteolytic activity for metastasis. Research-grade recombinant uPA serves as a tool to study cell signaling, angiogenesis, and tissue repair mechanisms. Current challenges include optimizing its specificity to minimize off-target effects and exploring targeted delivery strategies for anticancer applications.
×
